Регистрация | Вход Вт, 18.05.21, 03:42 | Приветствую Вас Гость | RSS
Современный Форум о ВИЧ
Новые сообщения · Правила форума · Поиск · Участники · RSS
Самая современная ВАКЦИНАЦИЯ ! [331 ответов]
Пн 17.05.21 23:40 от Mimik
Частная инфекционная клиника (г.Москва) [880 ответов]
Пн 17.05.21 17:09 от Untransmittable
Начало терапии. Выбор АРВТ. Рекомендации. [8390 ответов]
Пн 17.05.21 17:06 от Untransmittable
Анализы: результаты, расшифровка. Выбор клиник. [846 ответов]
Вс 16.05.21 20:25 от Pasha11
Отношения [83 ответов]
Вс 16.05.21 20:18 от Aljosha
Здравствуйте! Принимайте пополнение...Часть[2] [9245 ответов]
Вс 16.05.21 11:00 от Нина
ИС и ВН. Статистика результатов. Часть 2. [944 ответов]
Пт 14.05.21 19:02 от vrednyy
Группы взаимопомощи для москвичей [68 ответов]
Ср 12.05.21 17:05 от ChildrenPlus

Кстати:
Вирус (от лат. virus - яд), - неклеточная форма жизни, представляющая собой крайне упрощенную паразитическую структуру, способную проникать в живую клетку и размножаться внутри нее.

ВИЧ+ Чат [ без политики ]
Форма входа
Логин:
Пароль:
ВИЧ+ Опрос
Ваш ВИЧ-статус:

Результаты · Архив опросов

Всего ответов: 2130
Хостинг от uCoz ::
  • Страница 1 из 1
  • 1
Модератор форума: Webmaster, ARK, DJ, ksyu  
Современный Форум о ВИЧ » ВИЧ+ » Терапия » Bionor объявляет многообещающие результаты анализа (Bionor Vacc-4x и ингибитор HDAC romidepsin (Istodax®))
Bionor объявляет многообещающие результаты анализа
NarkozistДата: Пн, 04.05.15, 08:35 | Сообщение # 1
Бронзовое перо форума
Пользователь
Откуда: городок
Сообщений: 98
Комплименты: 9
Offline
Indicating killing of reactivated HIV virus and reduction in latent viral reservoir when patients receive the therapeutic vaccine Vacc-4x prior to romidepsinThe study confirms that Bionor’s proprietary peptide vaccine, Vacc-4x, is a safe and tolerated potential functional cure for HIV(Oslo, Norway, 4 May 2015) Bionor Pharma ASA (OSE:BIONOR), a peptide vaccine company advancing the potential first therapeutic vaccine towards a functional cure for HIV, today announces promising results from an interim analysis of Part B of the REDUC study. In the study, Bionor’s safe and tolerated vaccine candidate Vacc-4x and the HDAC inhibitor romidepsin (Istodax®, Celgene) are explored as a possible treatment regimen to reduce the persistent latent viral reservoir in HIV infected patients on anti-retroviral treatment.The REDUC study is a Phase I/II trial, and a first step in validating Bionor’s strategy for Vacc-4x which the company sees as a component in a potential functional cure for HIV.HIV treatment has evolved significantly in recent decades but the latent reservoir – in which the virus is dormant but invisible to anti-retroviral therapy – is a significant roadblock to managing HIV infection. In previous clinical trials, Vacc-4x demonstrated a significant reduction of HIV viral load set point and a long-term immune response in infected patients, supporting the company’s strategy to take Vacc-4x forward as a cure regimen for HIV. Vacc-4x has been designed to elicit a cell-based immune response by generating T-cells which can recognize and destroy infected HIV cells. In Part B of the REDUC study, Bionor combined Vacc-4x with romidepsin, which can reactivate and “kick awake” latent viral reservoirs.In 2012 the HIV market generated sales of roughly $17 billion from the sale of anti-retroviral therapies. According to the Centers for Diseases Control, of the 1.1 million Americans with HIV, only 33% are prescribed anti-retrovirals, of which around three quarters are virally suppressed. HIV patients treated with anti-retrovirals face a lifetime of daily pills, often with side-effects and long-term health implications1 including cardiovascular disease, kidney, liver and bone problems.The interim analysis announced today re-confirms that administration of romidepsin leads to activation of the virus in infected CD4+ T cells. Further, the results suggest that administration of Vacc-4x prior to an HDAC inhibitor enables killing of re-activated virus, as virus in plasma after reactivation is low or undetectable. Finally, results indicate a reduction of total HIV DNA levels in CD4+ cells, a measure used as surrogate for the size of the latent viral reservoir.The interim analysis shows:
• viral load remained below the level of quantification in 7 out of 9 patients
• increases in histone acetylation levels correlating to the time of romidepsin-infusions, demonstrating the pharmacodynamic effect of romidepsin
• a rapid and temporary viral reactivation in CD4+ T cells following romidepsin-infusions
• the combination of Vacc-4x and romidepsin was safe and well toleratedBionor’s President and Chief Executive Officer, Dr. David H. Solomon, commented: “These results are an important milestone for Bionor in establishing the ability of Vacc-4x to ‘kill’ activated HIV virus and infected CD4 cells following romidepsin (Istodax®) reactivation of the latent HIV reservoir and to reduce the latent reservoir in HIV patients while on cART. They bring us a step further toward our goal of advancing treatments towards a functional cure for HIV, and we look forward to progressing with the next stage of the study.Bionor is now the company with the most advanced therapeutic vaccine in development for a functional cure for HIV, and despite the challenges faced by the healthcare industry to date, our data validates that Vacc-4x represents the potential for a real breakthrough for HIV patients and caregivers.”Next results will be in H2 2015 with the final report in January 2016 and are expected to be published in a peer-review journal.Notes for EditorsAbout Bionor
Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company’s focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV.Bionor Pharma’s current clinical development pipeline comprises two vaccine candidates for the treatment of HIV, Vacc-4x and Vacc-C5. Vacc-4x is the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Bionor Pharma’s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through a collaboration with Celgene Corp, is investigating Vacc-4x and romidepsin in the REDUC study.Bionor is listed on the Oslo stock exchange, under the ticker BIONOR.More information about Bionor is available at www.bionorpharma.com.About the Trial
An Open Phase I/IIa Study to Evaluate the Safety and Effect of Therapeutic HIV-1 Immunization using Vacc-4x + rhuGM-CSF, and HIV-1 Reactivation using romidepsin, on the Viral Reservoir in Virologically Suppressed HIV-1 Infected Adults on cART, “REDUC”. Further details of the study are available on www.clinicaltrials.gov (NCT02092116).The study’s principal objective is to measure the effect of treatment with Vacc-4x + rhuGM-CSF and cyclic romidepsin treatment on the HIV-1 latent reservoir in HIV-infected patients virologically suppressed on cART. The interim analysis was conducted to reconfirm that administration of romidepsin leads to activation of virus in infected CD4+ T cells and to assess a possible reduction of the latent viral reservoir provided by administration of Vacc-4x prior to romidepsin infusion. Further, the safety and tolerability was assessed. The interim analysis included nine out of 20 patients enrolled in the REDUC Part B study. All patients received six injections of Vacc-4x prior to administration of one cycle of romidepsin (three infusions).The study was conducted in collaboration with Aarhus University Hospital, Denmark, which is leading research into the use of HDIs to reactivate latent reservoirs, and is part-funded by the Research Council of Norway GLOBVAC programme.The company is now exploring how to exploit the characteristics of Vacc-4x to develop a functional cure for HIV.For more information please contact:
Bionor Pharma ASA
President and Chief Executive Officer David Solomon:
Tel +0045 22 20 63 00Consilium Strategic Communications
Mary-Jane Elliott / Ivar Milligan / Jessica Hodgson / Hendrik Thys
bionor@consilium-comms.com
Tel: +44 (0)20 3709 5700
 
Современный Форум о ВИЧ » ВИЧ+ » Терапия » Bionor объявляет многообещающие результаты анализа (Bionor Vacc-4x и ингибитор HDAC romidepsin (Istodax®))
  • Страница 1 из 1
  • 1
Поиск:
ВИЧ+ Популярные Темы
Жизнь+ Самые Обсуждаемые
Гепатит C. Лечение. Опыт жизни с ГепС. Часть 1. [9990 ответов]
Здравствуйте! Принимайте пополнение... [9963 ответов]
ИС и ВН. Статистика результатов. Часть 1. [9897 ответов]
Здравствуйте! Принимайте пополнение...Часть[2] [9245 ответов]
Начало терапии. Выбор АРВТ. Рекомендации. [8390 ответов]
Новосибирск!!! Ау! [6520 ответов]
Самая современная терапия. Обзор исследований [6315 ответов]
Подскажите пожалуйста. Общие вопросы [5496 ответов]
С чего начать? [5219 ответов]
Побочные эффекты терапии. Смена АРВТ. [3111 ответов]
Геополитические процессы вокруг Украины [9985 ответов]
Украина - Россия: дубль два [9535 ответов]
Сумасшедшие, объединяйтесь!!! [2357 ответов]
Все в сад! Вы там будете петь? Нет, вы там будете слушать! ) [2278 ответов]
Какие кины смотрим ??? [2202 ответов]
Кто какую музыку слушает [1613 ответов]
Помойка [1570 ответов]
Православный взгляд [1293 ответов]
Хочу найти половинку)) [1266 ответов]
Хочу !!!!!!!!!!!! [1259 ответов]

Покупка/Продажа/Обмен АРТ [1163 ответов]
Пн 17.05.21 23:42 от Taurus
Отдам, приму в дар препараты! [499 ответов]
Вс 16.05.21 07:14 от Genos
Z_Z отзовись! [2 ответов]
Пт 14.05.21 17:42 от Unforgiven
Общение, поддержка, знакомства. [3 ответов]
Чт 13.05.21 20:26 от Космос
Хочу найти половинку)) [1266 ответов]
Ср 12.05.21 12:28 от Torul
Горячие вопросы [22 ответов]
Сб 01.05.21 00:52 от 68кошка68
Украина - Россия: дубль два [9535 ответов]
Сб 17.04.21 16:38 от paisii
Как так получается? [0 ответов]
Сб 17.04.21 00:25 от hivhelp
Покупка/Продажа/Обмен АРТ [1163 ответов]
Пн 17.05.21 23:42 от Taurus
Вот уже 10 лет нахожу у себя симптомы вич [21 ответов]
Пн 17.05.21 02:17 от Nikolay
вероятность заражения!ответте пожалуйста [5 ответов]
Чт 06.05.21 18:28 от Anna2704
Какому заболеванию присущи следующие симптомы? [9 ответов]
Чт 06.05.21 18:26 от Anna2704

Угадай, что это [90 ответов]
Пн 19.10.20 20:38 от Klaipeda
Хорошо-Плохо [64 ответов]
Пн 19.10.20 20:36 от Klaipeda
Игра "Превращения" [4077 ответов]
Пн 10.08.20 07:35 от @lexs
Игра "Угадай Два Слова" [2409 ответов]
Вс 02.08.20 18:35 от JustBTboy
Города [1833 ответов]
Ср 15.07.20 15:41 от OLLIKA

Обратная Связь Карта Сайта